Prediction of residual metabolic activity after treatment in NSCLC patients

References

• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–81.
   PubMed Web of Science ®Google Scholar
• Brawner EJ, Patrick Nana-Sinkam S, Jett JR. Lung cancer screening in 2008: A review and update. Respir Med CME 2008;1:2–9.
   Google Scholar
• Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines, 2nd ed. Chest 2007;132:S234–S42.
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, . Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417–23.
   PubMed Web of Science ®Google Scholar
• Florin Sirzén EK, Sörenson S, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003;42:493–515.
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, . Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004;46:87–98.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, . Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386–92.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Bosmans G, van Baardwijk AA, Dekker AL, Oellers MC, Lambin P, . Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: A prospective study. Int J Radiat Oncol Biol Phys 2008;71: 1402–7.
   PubMed Web of Science ®Google Scholar
• Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 2007;48 (Suppl 1):S36–S44.
   Google Scholar
• Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005;49:95–108.
   PubMed Web of Science ®Google Scholar
• Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, . Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362–70.
   PubMed Web of Science ®Google Scholar
• van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, . Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010;28:1380–6.
   PubMed Web of Science ®Google Scholar
• Steel G. Basic clinical radiobiology, 3rd. London: Hodder Arnold Publications; 2002.
   Google Scholar
• Fung GM, Mangasarian OL. Multicategory proximal support vector machine classifiers. Mach Learn 2005;59:77–97.
   Web of Science ®Google Scholar
• Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, . Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008;62: 55–61.
   PubMed Web of Science ®Google Scholar
• Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903–9; Discussion 1909.
   PubMed Web of Science ®Google Scholar
• Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, . Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000; 27:861–6.
   PubMedGoogle Scholar
• Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998;9:1193–8.
   PubMed Web of Science ®Google Scholar
• Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002;122:1037–57.
   PubMed Web of Science ®Google Scholar
• Dehing-Oberije C, De Ruysscher D, van der Weide H, Hochstenbag M, Bootsma G, Geraedts W, . Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039–44.
   PubMed Web of Science ®Google Scholar
• Solan MJ, Werner-Wasik M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 2003;21:64–73.
   PubMedGoogle Scholar
• Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 2010;68:398–402.
   PubMed Web of Science ®Google Scholar
• Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: Analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005;127:768–77.
   PubMed Web of Science ®Google Scholar
• Ball D, Smith J, Wirth A, Mac Manus M. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002;54:1007–13.
   PubMed Web of Science ®Google Scholar
• Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459–64.
   PubMed Web of Science ®Google Scholar
• Forssell-Aronsson E, Kjellén E, Mattsson S, Hellström M, Swedish Cancer Society Investigation Group T. Medical imaging for improved tumour characterization, delineation and treatment verification. Acta Oncol 2002;41: 604–14.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, . High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324–33.
   PubMed Web of Science ®Google Scholar
• Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, . Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74:355–62.
   PubMed Web of Science ®Google Scholar
• Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137–48.
   PubMed Web of Science ®Google Scholar
• Henning Willers FW, Bünemann H, Heilmann H-P. High-dose radiation therapy alone for inoperable non-small cell lung cancer: Experience with prolonged overall treatment times. Acta Oncol 1998;37:101–5.
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, . A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781–92.
   PubMed Web of Science ®Google Scholar
• Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, . 4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index. Lancet Oncol 2006;7:829–36.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007;2(Suppl 2):S68–S76.
   Google Scholar
• Naqa IE, Deasy JO, Mu Y, Huang E, Hope AJ, Lindsay PE, . Datamining approaches for modeling tumor control probability. Acta Oncol Epub 2010 Mar 2.
   Web of Science ®Google Scholar
• Encan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol 1990;29:151–4.
   PubMed Web of Science ®Google Scholar